Edinburgh-based MedTech Trogenix has raised £70 million in a Series A funding round to accelerate the development of its next-generation cancer therapies targeting aggressive solid tumours. The investment, led by IQ Capital, will enable the company to advance its lead programme in glioblastoma and a follow-on programme in colorectal cancer liver metastases. It will also … Continue reading Trogenix raises £70m to accelerate cancer therapies